logo

Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2014 / Article / Tab 2

Review Article

Aspirin Resistance and Promoting Blood Circulation and Removing Blood Stasis: Current Situation and Prospectives

Table 2

Clinical trials of Chinese herbal interventions in treating AR with a concomitant population.
Reference (year)Study designParticipants T/CIntervention (herb included)ControlOutcome measureTreatment durationMain finding ( value)
Chai et al. (2008) [48]RCT10/10Composite salvia dropping pill (10 pills, tid); aspirin (100 mg, qd)Aspirin (100 mg, qd) Platelet aggregation rate induced by AA and ADP2 wComposite salvia dropping pill can enhance patients’ sensitivity to aspirin. The combining use can synergisticly exert antiplatelet effect.
Peng et al. (2011) [49]RCT12/13Huo xue capsule (4 pills, tid); aspirin (100 mg, qd)Aspirin (100 mg, qd)Platelet aggregation rate induced by AA and ADP12 wThe combination of huo xue capsule and aspirin can decrease the platelet aggregation rate significantly.
Yang et al. (2011) [50]RCT130/130Nao xin tong capsule (2 pills, tid); aspirin (100 mg, qd)Aspirin (100 mg, qd) Platelet aggregation rate induced by AA and ADP, the incidence of AR and ASR of each group.24 wThe combining use of nao xin tong capsule and aspirin can significantly decrease the platelet aggregation rate. Incidence of AR and ASR is lower than single aspirin group.
Yin et al. (2010) [51]RCT30/29Tong xin luo capsule (3 pills, tid); aspirin (100 mg, qd)Aspirin (100 mg, qd) COL and platelet aggregation rate induced by AA and ADP30 dTong xin luo capsule has some effects on decreasing the platelet aggregation rate induced by ADP and COL.
Song (2008) [52]RCT24/23Tong xinluo capsule (4 pills, tid)Clopidogrel (75 mg, qd) CRP, TXB2, and platelet aggregation rate induced by AA and ADP30 dTongxinluo capsule has antiplatelet aggregation and anti-inflammatory effect in ACS patients with AR and can improve AR in ACS patients in a certain degree.
Liu (2011) [53]RCT30/30Xinnao shutong capsule (9 pills, qd); aspirin (100 mg, qd)Aspirin (100 mg, qd) Uric acid, Blood lipid, Hs-CRP, TXB2, and platelet aggregation rate induced by AA and ADP
AA, ADP, and so on.		1 yThe combining use of aspirin and xinnao shutong capsule can decrease the adverse cadiovascular events of patients with AR.
Wu (2012) [54]RCT30/30Xuefu zhuyu decoction (1 dose, qd); aspirin (100 mg, qd)Aspirin (100 mg, qd) The expression of AA and ADP in serum.4 wThe combining use of aspirin and Xuefu zhuyu decoction can significantly decrease the platelet aggregation rate induced by ADP and AA.
Luo et al. (2012) [55]RCT30/30Zhilong huoxue capsule (1.6 g, tid)Aspirin (300 mg, qd) The mean platelet aggregation rate, TXB2, and 6-K-PGF1α.4 wCapsule zhilong huoxue of aspirin resistance has better efficacy and safety. The mechanism may be related to its effect of decreasing TXB2, increasing 6-K-PGF1α, and decreasing TXB2/6-K-PGF1α.
Xiu (2012) [56]RCT30/30Di’ao xinxuekang capsule (1.6 g, tid)Aspirin (300 mg, qd) Platelet aggregation rate induced by AA and ADP4 wCapsule di’ao xinxuekang of aspirin resistance has better efficacy and safety. The mechanism may be related to its effect of decreasing TXB2, increasing 6-K-PGF1α, and decreasing TXB2/6-K-PGF1α.
Yang et al. (2011) [57]RCT50/50Ginkgo biloba extract (19.2 mg, tid); aspirin (100 mg, qd)Aspirin (100 mg, qd) Platelet aggregation rate induced by AA, ADP, and FAP2 wCombination of ginkgo biloba extract and low dosage of aspirin can decrease AR and decrease incidence of adverse cadiovascular events.
Notes: T/C: treatment group and control group; CT: clinical trial; RCT: randomized clinical trial; NR: not reported; ADP: adenosine diphosphate; COL: collagen.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.